DAJY(SZ:002030)2022-12-07 08:32Group 1: Company Overview - The company is called Da An Gene Co., Ltd., with the stock code 002030 [1] - The investor relations activity was conducted on November 18, 2015, at the company headquarters in Guangzhou [4] Group 2: Participants in the Investor Relations Activity - Participants included representatives from various investment firms, such as Shenzhen Qianhai Qilong Fund Management Co., Ltd. and China Orient Capital Research Institute [3][4] Group 3: Key Questions and Answers - PCR diagnostic reagents are included in the medical insurance coverage and are considered routine testing reagents [5] - The company aims to become a leading integrated supplier in China's diagnostic industry, with a focus on high-tech biopharmaceuticals [5] - The company’s PCR reagent products are primarily sold through direct sales, while other products use a combination of direct sales and agency models [6] - The company covers over 2,000 hospitals with its PCR diagnostic reagent products, with approximately 70% of these being tertiary hospitals [6] Group 4: Future Plans and Challenges - The company is in the early stages of hospital investment, with future plans dependent on development models and national policies [6] - There are considerations for expanding independent laboratories in collaboration with hospitals, reflecting changes in the independent laboratory development model [6] - The increase in operating costs outpacing revenue growth is attributed to the company's efforts in industry chain layout, which involves higher labor, research, and equipment costs [7]